Payment overview · 2025
General Payments
$572.39
31 reported records · 15 companies
Healthcare provider profile · identity verified
Cheri Owens Vachtsevanos, MD
Allopathic & Osteopathic Physicians|Internal Medicine · GAINESVILLE, GA · NPI 1609844067
Verified facts
What the public records show
CMS Open Payments records show Cheri Owens Vachtsevanos, MD received $572.39 in general payments during 2025 across 31 reported records.
AstraZeneca Pharmaceuticals LP accounted for 16.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $94.13 | 16.4% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $73.13 | 12.8% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $62.65 | 10.9% | 3 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $57.85 | 10.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $46.47 | 8.1% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.94 | 6.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.50 | 5.7% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $32.15 | 5.6% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.67 | 5.2% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $25.79 | 4.5% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $19.61 | 3.4% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $17.81 | 3.1% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.73 | 2.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.52 | 2.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.44 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $572.39 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $62.65 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $62.65 | 3 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $57.85 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $51.72 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $46.47 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $46.47 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $34.94 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $32.15 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $29.67 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $28.33 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $25.79 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $23.93 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $22.42 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.41 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.41 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $17.81 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.51 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.52 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.52 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 118 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 48 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 103 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 85 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
102 | 25 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
25 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
48 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
103 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
85 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
118 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 906 | 288 |
| Levothyroxine Sodium | Levothyroxine Sodium | 647 | 170 |
| Amlodipine Besylate | Amlodipine Besylate | 565 | 170 |
| Losartan Potassium | Losartan Potassium | 563 | 166 |
| Metoprolol Succinate | Metoprolol Succinate | 479 | 137 |
| Atorvastatin Calcium | Atorvastatin Calcium | 467 | 153 |
| Pantoprazole Sodium | Pantoprazole Sodium | 459 | 145 |
| Omeprazole | Omeprazole | 321 | 108 |
| Famotidine | Famotidine | 256 | 81 |
| Gabapentin | Gabapentin | 254 | 81 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 238 | 63 |
| Meloxicam | Meloxicam | 222 | 84 |
| Metformin Hcl | Metformin Hcl | 216 | 63 |
| Escitalopram Oxalate | Escitalopram Oxalate | 193 | 62 |
| Sertraline Hcl | Sertraline Hcl | 188 | 62 |
| Ezetimibe | Ezetimibe | 176 | 49 |
| Lisinopril | Lisinopril | 157 | 50 |
| Montelukast Sodium | Montelukast Sodium | 157 | 49 |
| Bupropion Xl | Bupropion Hcl | 150 | 42 |
| Mounjaro | Tirzepatide | 149 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 147 | 37 |
| Trazodone Hcl | Trazodone Hcl | 143 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 132 | 72 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 132 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 131 | 40 |
| Clonidine Hcl | Clonidine Hcl | 128 | 44 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 128 | 37 |
| Carvedilol | Carvedilol | 123 | 40 |
| Potassium Chloride | Potassium Chloride | 122 | 48 |
| Eliquis | Apixaban | 118 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 112 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 108 | 32 |
| Tramadol Hcl | Tramadol Hcl | 105 | 41 |
| Hydralazine Hcl | Hydralazine Hcl | 103 | 26 |
| Jardiance | Empagliflozin | 103 | 22 |
| Synthroid | Levothyroxine Sodium | 102 | 25 |
| Alendronate Sodium | Alendronate Sodium | 100 | 43 |
| Simvastatin | Simvastatin | 99 | 30 |
| Furosemide | Furosemide | 95 | 36 |
| Mirtazapine | Mirtazapine | 95 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 95 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 95 | 41 |
| Quetiapine Fumarate | Quetiapine Fumarate | 93 | 29 |
| Clonazepam | Clonazepam | 92 | 31 |
| Doxycycline Hyclate | Doxycycline Hyclate | 92 | 76 |
| Allopurinol | Allopurinol | 91 | 23 |
| Ozempic | Semaglutide | 85 | 15 |
| Alprazolam | Alprazolam | 74 | 34 |
| Buspirone Hcl | Buspirone Hcl | 73 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 63 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 61 | 24 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 61 | 52 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 58 | 22 |
| Valsartan | Valsartan | 57 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 55 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 51 | 48 |
| Ondansetron Odt | Ondansetron | 51 | 30 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 51 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 49 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 48 | 39 |
| Farxiga | Dapagliflozin Propanediol | 48 | 12 |
| Metformin Hcl Er | Metformin Hcl | 48 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 47 | 12 |
| Celecoxib | Celecoxib | 45 | 16 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 44 | 14 |
| Prednisone | Prednisone | 44 | 42 |
| Glipizide Er | Glipizide | 43 | 12 |
| Fluconazole | Fluconazole | 42 | 34 |
| Estradiol | Estradiol | 39 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | 12 |
| Finasteride | Finasteride | 37 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 34 |
| Paroxetine Hcl | Paroxetine Hcl | 36 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 35 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 34 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Trulicity | Dulaglutide | 33 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 33 | 12 |
| Xarelto | Rivaroxaban | 33 | 12 |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | 13 |
| Atenolol | Atenolol | 30 | suppressed |
| Levofloxacin | Levofloxacin | 30 | 26 |
| Cephalexin | Cephalexin | 29 | 25 |
| Chlorthalidone | Chlorthalidone | 29 | suppressed |
| Glipizide | Glipizide | 29 | suppressed |
| Irbesartan | Irbesartan | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Spironolactone | Spironolactone | 27 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Prolia | Denosumab | 25 | 17 |
| Torsemide | Torsemide | 24 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | 20 |
| Tradjenta | Linagliptin | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | 12 |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 14 |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Premarin | Estrogens, Conjugated | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 13 |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | 11 |
| Mesalamine | Mesalamine | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 11 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $572.39 · 31 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, BREZTRI, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, ELIQUIS, FARXIGA, GARDASIL 9, INSPIRE, JARDIANCE, Korlym, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, SAPIEN 3 Ultra RESILIA, Senza, UBRELVY, VOQUEZNA, XIFAXAN | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error